TEC family kinase · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13TEC family kinase shows approved-linked disease relevance led by alopecia areata. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q08881. Start with alopecia areata, then reuse UniProt Q08881 as the stable protein anchor across project notes and exports.
Start with alopecia areata, then reuse UniProt Q08881 as the stable protein anchor across project notes and exports.
TEC family kinase shows approved-linked disease relevance led by alopecia areata. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with alopecia areata because it currently carries approved-linked support. Linked drugs include RITLECITINIB, RITLECITINIB TOSYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyTyrosine-protein kinase ITK/TSK
Review this target as TEC family kinase, mapped to UniProt Q08881. ChEMBL maps the protein component as Tyrosine-protein kinase ITK/TSK. Sequence length is 620 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats TEC family kinase as ChEMBL target CHEMBL4296642, mapped to UniProt Q08881. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether TEC family kinase is the right protein anchor across sources, using UniProt Q08881 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why alopecia areata is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | TEC family kinase |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | Q08881 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Tyrosine-protein kinase ITK/TSK |
| UniProt Accession | Q08881 |
| Component Type | Protein |
| Sequence Length | 620 aa |
Tyrosine-protein kinase ITK/TSK
Review this target as TEC family kinase, mapped to UniProt Q08881. ChEMBL maps the protein component as Tyrosine-protein kinase ITK/TSK. Sequence length is 620 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
TEC family kinase shows approved-linked disease relevance led by alopecia areata. 5 more disease programs remain visible in the same review block.
Start review with alopecia areata because it currently carries approved-linked support. Linked drugs include RITLECITINIB, RITLECITINIB TOSYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.